To date, Ceres has filed patent applications on over 50,000 full-length functionally annotated genes and over 10,000 promoter sequences
Ceres places a large emphasis on the generation and protection of intellectual property. Ceres’ intellectual property strategy leverages three major competitive advantages: (1) the ability to discover and sequence full-length genes in a high-throughput manner, (2) an integrated suite of genomic technologies which enables Ceres to ascribe specific utilities to a very high proportion of the genes that it discovers, and (3) information management systems which enable the rapid and accurate filing and follow-up of thousands of patent applications.
Ceres practices a proprietary technology for capturing and sequencing full-length cDNAs. Unlike ESTs, these sequences cover the complete and accurate open reading frame of a gene giving the information necessary for a cell to manufacture the encoded protein. Genomic sequence can sometimes give equivalent information, but accurate predictions of gene structure from genomic sequence are only accurate in approximately 50% of the cases tested. The US Patent and Trademark Office has indicated that accurate full-length genes are necessary for the issuance of composition of matter claims that cover the production of the encoded protein. In addition, at least one substantial and practical utility must be described for a particular gene sequence. Ceres’ integrated genomics engine enables the description of multiple utilities for any given gene. The combination of this utility information and the full-length gene sequences should enable Ceres to gain intellectual property protection for a large portfolio of important plant genes.
The generation and integration of such a large amount of data into accurate patent application submissions requires a sophisticated information management effort. Ceres has designed and incorporated information management technologies into its technology platforms to enable the timely and accurate generation of thousands of patent applications. To date, Ceres has filed patent applications on over 50,000 full-length functionally annotated genes and over 10,000 promoter sequences.
April 3, 2002
Monsanto and Ceres Announce Important Product Discovery and Development Collaboration
St. Louis, Missouri and Los Angeles, California — Monsanto Company and Ceres, Inc. today announced an important product discovery and development collaboration focused on applying genomics technologies to provide improvements in certain agricultural crops.
“Our new alliance with Ceres provides us access to a proprietary knowledge base that will accelerate Monsanto’s product pipeline. By marrying the complementary genomics capabilities of Ceres with the product development capabilities of Monsanto, we will be in a position to deliver additional value to farmers worldwide,” said Hendrik Verfaillie, chief executive officer of Monsanto.
Walter De Logi, chief executive officer of Ceres, said, “Monsanto is an ideal partner for Ceres because it is a leader in providing biotechnology-based agricultural products to the world’s farmers. Monsanto has the resources to give Ceres’ technology the widest possible distribution. Furthermore, we share a vision of providing abundant food and a healthy environment around the world.”
Under the collaboration, Monsanto will acquire rights to Ceres technologies in certain crops and applications in exchange for payments over several years. Ceres will receive additional payments subject to meeting specified objectives for developing additional related technology, as part of its continuing commitment to genomics-based product discovery. Monsanto will also fund a jointly implemented research program and has made a minority equity investment in Ceres. Expected payments to Ceres under the collaboration are $137 million over several years plus potential royalties.
As part of the collaboration, Monsanto and Ceres have agreed to make technologies accessible to farmers in developing countries, including non-profit humanitarian applications not served by commercial markets or research and development investments. This innovative feature of the collaboration reflects the commitment of both companies to bring the benefits of science and technology to society through public-private partnerships to improve subsistence crops, in addition to the commercial development of products around the world.
Ceres, Inc. is a privately held biotechnology company utilizing multiple integrated plant genomics technologies to develop innovative products. In addition to pursuing opportunities in the food, feed and fiber industries, Ceres’ business strategy consists of leveraging its technology platform in the agrochemical, chemical and pharmaceutical industries.
Monsanto Company (NYSE: MON) is a leading provider of agricultural solutions to growers worldwide. Monsanto’s employees provide top-quality, cost-effective and integrated approaches to help farmers improve their productivity and produce better quality foods. For more information on Monsanto, see: www.monsanto.com.
Ceres Announces Genomics Milestone in Energy Crop Enhancement Program (info)
12,000 full-length switchgrass genes sequenced and genetic variation characterized
THOUSAND OAKS, CA – July 10, 2006
Contact: Ceres, Inc. Shirley Bell email@example.com
MONSANTO COLLABORATES WITH CERES
Monsanto Company and the privately owned biotechnology company, Ceres Inc, Los Angeles, have announced collaboration to apply genomics technologies to provide improvements in agricultural crops. “Our new alliance with Ceres provides us access to a proprietary knowledge base that will accelerate Monsanto’s product pipeline. By marrying the complementary genomics capabilities of Ceres with the product development capabilities of Monsanto, we will be in a position to deliver additional value to farmers worldwide,” said Hendrik Verfaillie, CEO of Monsanto.
Under the collaboration, Monsanto will acquire rights to technologies in certain crops and applications in exchange. Expected payments to Ceres through the deal will be $137 million over several years as well as possible royalties. Monsanto and Ceres have also agreed to make some technologies accessible to farmers in developing countries, including non-profit humanitarian applications.
Crop Protection Monthly – 30 April 2002, Issue No. 149
Published by: Market Scope Europe Ltd
Editor: Brian R. Hicks